Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
CAMBRIDGE, Mass., Feb. 29, 2016 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a company overview at the upcoming Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016 at 2:40 p.m. ET in Boston, MA.
A live webcast of the presentation can be accessed by visiting the “Events and Presentations” tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.
About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at www.genocea.com.
For media: Liz Bryan Spectrum Science Communications, Inc. O: 202-955-6222 [email protected] For investors: Jonathan Poole Genocea Biosciences, Inc. O: 617-876-8191 [email protected]
